NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
73 trialsNCT04008238 2026-03-06
PIPER
Institut Bergonié
Phase NA Completed
NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04383119 2026-01-02
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT02234050 2025-07-10
Trabectedin for Recurrent Grade II/III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT05597917 2025-04-04
TRABTRAP
Universität Münster
Phase 3 Recruiting
NCT06524583 2025-03-30
L-UteCIN
UNICANCER
Phase 2 Recruiting
NCT03164980 2025-03-20
COMPASS
North Eastern German Society of Gynaecological Oncology
Phase 4 Terminated
NCT03138161 2025-02-24
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 1/2 Recruiting
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT03023124 2024-12-09
STRADA
Italian Sarcoma Group
Phase 2 Completed
NCT03127215 2024-05-08
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02367924 2023-06-22
YonSar
PharmaMar, Spain
Completed
NCT02275286 2023-05-31
TRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Recruiting
NCT05868889 2023-05-24
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT05131386 2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
NCT02359474 2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT03074318 2022-04-29
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03690739 2022-02-24
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Terminated
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT02247544 2021-11-01
TRAVELL
Italian Sarcoma Group
Phase 2 Completed
NCT02825420 2021-10-29
NIMES-ROC
PharmaMar
Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT02398058 2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1 Completed
NCT02929394 2020-09-02
Trabectedin Maintenance Post 1st-line in STS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT04394728 2020-05-19
Metabol-STS
Centro di Riferimento Oncologico - Aviano
Completed
NCT02194231 2020-01-23
ATREUS
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01735071 2019-11-19
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT02793050 2019-05-10
TrObs
Italian Sarcoma Group
Completed
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT03496519 2018-10-09
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
Phase 1 Withdrawn
NCT00070109 2018-09-14
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT02672527 2018-08-16
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT02066675 2018-04-11
TR1US
Italian Sarcoma Group
Phase 2 Completed
NCT03446495 2018-02-26
Renaissance
Scientific Medical Society, Kazakhstan
Unknown
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00210665 2017-10-10
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
No longer available
NCT01453283 2017-07-02
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed